Rituximab-induced vasculitis: A case report and review of the medical published work.
Rituximab is an anti-CD20 chimeric murine/human monoclonal antibody mainly used in the treatment of patients with a cutaneous lymphoid malignancy. Among the side-effects associated with rituximab administration, vasculitis has been rarely reported. There are two reported cases in the English language medical published work. We describe a 38-year-old Korean man with cutaneous vasculitis occurring 1 day after rituximab administration.
Kim
Min Joo
MJ
Department of Dermatology, College of Medicine, The Catholic University of Korea, Seoul 137-701, Korea.
Kim
Hyung Ok
HO
Kim
Ho Yeon
HY
Park
Young Min
YM
D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D006801:Humans; D008297:Male; D000069283:Rituximab; D012867:Skin / Q000473:pathology; D018366:Vasculitis, Leukocytoclastic, Cutaneous / Q000139:chemically induced* / Q000473:pathology
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D000069283:Rituximab